<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02502773</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0242</org_study_id>
    <secondary_id>2014-005575-84</secondary_id>
    <nct_id>NCT02502773</nct_id>
  </id_info>
  <brief_title>Fluid Loading in Abdominal Surgery: Saline Versus Hydroxyethyl Starch (FLASH Study)</brief_title>
  <acronym>FLASH</acronym>
  <official_title>Fluid Loading in Abdominal Surgery: Saline Versus Hydroxyethyl Starch: A Double-blinded Multicenter Prospective Randomized Trial (FLASH Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agence Nationale de sécurité du Médicament</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Programme Hospitalier de Recherche Clinique (AOI N° 2013 _ Futier)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Société Française Anesthesie-Réanimation (SFAR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to evaluate whether the type of fluid (0.9% saline or 6%&#xD;
      Hydroxyethyl starch 130/0.4) in the context of an individualized goal-directed fluid therapy&#xD;
      is associated with a difference in morbidity and mortality within the first 14 days in&#xD;
      patients at moderate-to-high risk of postoperative complications after abdominal surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fluid administration is the mainstay treatment for suspected hypovolemia during surgery, but&#xD;
      the effects of different crystalloid and colloid solutions on outcome remain poorly explored&#xD;
      in surgical patients.&#xD;
&#xD;
      Two recent international multicenter studies (6S and CHEST studies) have shown that, compared&#xD;
      to crystalloid solutions, the use of hydroxyethyl starch (HES) could be responsible for&#xD;
      higher morbidity, especially renal failure, and mortality in ICU patients, thus leading to a&#xD;
      recent restriction of their range of indications.&#xD;
&#xD;
      In contrast, in surgical patients, recent meta-analyses have concluded on the absence of&#xD;
      difference in terms of mortality and postoperative renal failure between crystalloids and&#xD;
      latest generation HES. Excessive fluid administration during surgery is associated with&#xD;
      increased risk of postoperative morbidity, including renal dysfunction and mortality. It has&#xD;
      been suggested that, compared with the volume-restoring effects of colloids, crystalloid use&#xD;
      may require the administration of higher fluid volumes, which may contribute to poorer&#xD;
      outcomes. In the surgical context, clinical trials and meta-analyses have shown that&#xD;
      individualized goal-direct fluid administration can reduce postoperative morbidity. Although&#xD;
      most GDT studies have used colloid solutions for fluid loading, the effects of the type of&#xD;
      fluids are currently unknown and crystalloids are proposed for first-line therapy.&#xD;
&#xD;
      The proposed Flash multicenter study will be conducted to assess if the use of HES or&#xD;
      crystalloid solutions during an individualized GDT contribute to outcome differences in&#xD;
      patients at moderate-to-high risk of postoperative complications after abdominal surgery. As&#xD;
      these fluids are widely used during surgery and because of current concerns about the risks&#xD;
      related to the use of HES-based products in ICU patients, the trial will provide important&#xD;
      data to clinicians involved in perioperative care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">October 22, 2018</completion_date>
  <primary_completion_date type="Actual">July 22, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal dysfunction</measure>
    <time_frame>during the first 14 postoperative days</time_frame>
    <description>Renal dysfunction (defined by KDIGO stage 1 or higher)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary complication</measure>
    <time_frame>during the first 14 postoperative days</time_frame>
    <description>Pulmonary complication (defined by the need for noninvasive or invasive ventilatory assistance for postoperative acute respiratory failure)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular complication</measure>
    <time_frame>during the first 14 postoperative days</time_frame>
    <description>Cardiovascular complication (defined by the development of acute heart failure)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infectious complication</measure>
    <time_frame>during the first 14 postoperative days</time_frame>
    <description>Infectious complication (defined by the development of sepsis, severe sepsis or septic shock)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgical complication</measure>
    <time_frame>during the first 14 postoperative days</time_frame>
    <description>Surgical complication (defined as the need for surgical reoperation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total fluid volume</measure>
    <time_frame>during the surgical period and the first 24 postoperative hours</time_frame>
    <description>Total fluid volume (0.9% saline and HES 130/0.4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of blood loss</measure>
    <time_frame>during the surgical period and the first 24 postoperative hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal complications : oliguria</measure>
    <time_frame>within 14 days</time_frame>
    <description>Postoperative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular complications</measure>
    <time_frame>within 14 days</time_frame>
    <description>Postoperative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory complications</measure>
    <time_frame>within 14 days</time_frame>
    <description>Postoperative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SIRS score</measure>
    <time_frame>within 14 days</time_frame>
    <description>Postoperative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious complications</measure>
    <time_frame>within 14 days</time_frame>
    <description>Postoperative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical complications</measure>
    <time_frame>within 14 days</time_frame>
    <description>Postoperative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity organ failure assessment score from postoperative</measure>
    <time_frame>Day-1 to Day-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unexpected ICU admission (or readmission) following surgery</measure>
    <time_frame>within 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lactate</measure>
    <time_frame>from Day-1 to Day-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>from Day-1 to Day-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma chloride</measure>
    <time_frame>from Day-1 to Day-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of units of packed red blood cells</measure>
    <time_frame>during the surgical period and the first 24 postoperative hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">826</enrollment>
  <condition>Postoperative Morbidity</condition>
  <condition>Postoperative Mortality</condition>
  <arm_group>
    <arm_group_label>crystalloid group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The proposed Flash multicenter study will be conducted to assess if the use of HES or crystalloid solutions during an individualized GDT contribute to outcome differences in patients at moderate-to-high risk of postoperative complications after abdominal surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>colloid group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The proposed Flash multicenter study will be conducted to assess if the use of HES or crystalloid solutions during an individualized GDT contribute to outcome differences in patients at moderate-to-high risk of postoperative complications after abdominal surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxethyl starch</intervention_name>
    <arm_group_label>colloid group</arm_group_label>
    <arm_group_label>crystalloid group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All adult patients who&#xD;
&#xD;
          -  Undergo elective or emergency abdominal surgery under general anesthesia&#xD;
&#xD;
          -  With an estimated surgical duration greater than or equal to 2 hours&#xD;
&#xD;
          -  With moderate-to-high risk of postoperative complications defined by an AKI risk&#xD;
             index≥ class 3, as defined by the presence of at least 4 of the following factors:&#xD;
             age&gt; 56 years, male gender, intraperitoneal surgery, active congestive heart failure,&#xD;
             ascites, hypertension, emergency surgery, mild or moderate renal insufficiency,&#xD;
             diabetes mellitus treated by oral or insulin therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The following patients will not be evaluated for inclusion:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Preoperative acute heart failure&#xD;
&#xD;
          -  Preoperative acute coronary insufficiency&#xD;
&#xD;
          -  Preoperative severe renal failure (defined by creatinine clearance &lt;30 ml/min or&#xD;
             requiring renal replacement therapy)&#xD;
&#xD;
          -  Preoperative shock defined by the need for vasoactive amines&#xD;
&#xD;
          -  History of allergy with the use of 6% Hydroxethyl starch 130/0.4&#xD;
&#xD;
          -  Contraindication to the use of HES: sepsis, burnt patient, renal insufficiency or&#xD;
             dialysis, cerebral hemorrhage, ICU patient , hypervolemia, lung edema, dehydration,&#xD;
             severe hypernatremia or severe hyperchloremia, severe hepatic insufficiency,&#xD;
             congestive heart failure, severe coagulopathy, organ transplant&#xD;
&#xD;
          -  Patient's or relative's refusal to participate&#xD;
&#xD;
          -  Parturient or breastfeeding woman&#xD;
&#xD;
          -  Protected major (guardianship)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel FUTIER</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Etienne BAZIN</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samir JABER</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julien POTTECHER</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre OUATTARA</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas LESCOT</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint-Antoine (APHP)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hélène BELOEIL</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilles LEBUFFE</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe CUVILLON</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nîmes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julien BUREY</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Tenon (APHP)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Willy-Serge MFAM</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH ORLEANS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincent PIRIOU</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU LYON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc LEONE</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sébastien BERTRAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nîmes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marion FAUCHER</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine PAUGAM-BURTZ</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Beaujon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lionel VELLY</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier HUET</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sigismond LASOCKI</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Angers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre SAINT-LEGER</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH VALENCIENNES</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>July 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2015</study_first_posted>
  <last_update_submitted>February 20, 2019</last_update_submitted>
  <last_update_submitted_qc>February 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Goal-directed therapy</keyword>
  <keyword>Fluid loading</keyword>
  <keyword>Abdominal surgery</keyword>
  <keyword>Postoperative morbidity</keyword>
  <keyword>Postoperative mortality</keyword>
  <keyword>Individualized goal-directed fluid therapy</keyword>
  <keyword>Elective or emergency abdominal surgery</keyword>
  <keyword>General Anesthesia</keyword>
  <keyword>Moderate-to-high risk surgical patients</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

